Eli Lilly is spending another $3 billion to bulk up manufacturing as the drugmaker seeks to stoke production of some blockbuster drugs and future products. Lilly said Thursday it will expand a ...
DealBook Summit, Lilly CEO David Ricks said GLP-1 drugs have the potential to treat more than obesity — including heart disease and substance use disorders.
Shares of Eli Lilly climbed early Wednesday after the drugmaker detailed a study showing that its blockbuster weight-loss drug Zepbound helped patients shed more pounds than Wegovy from rival Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback